{
    "id": "dbpedia_2348_3",
    "rank": 11,
    "data": {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001454-18/DK",
        "read_more_link": "",
        "language": "en",
        "title": "Clinical Trials Register",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://www.clinicaltrialsregister.eu/ctr-search/img/euFlag.png",
            "https://www.clinicaltrialsregister.eu/ctr-search/img/printer.png",
            "https://www.clinicaltrialsregister.eu/ctr-search/img/ema_logo.png",
            "https://www.clinicaltrialsregister.eu/ctr-search/img/hma_logo.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "D.IMP: 2 D.1.2 and D.1.3IMP RoleTest D.2 Status of the IMP to be used in the clinical trial D.2.1IMP to be used in the trial has a marketing authorisation Yes D.2.1.1.1Trade name Sendoxan (cyclophosphamide) D.2.1.1.2Name of the Marketing Authorisation holderBaxter D.2.1.2Country which granted the Marketing AuthorisationDenmark D.2.5The IMP has been designated in this indication as an orphan drug in the Community No D.2.5.1Orphan drug designation number D.3 Description of the IMP D.3.1Product nameSendoxan D.3.4Pharmaceutical form Infusion D.3.4.1Specific paediatric formulation No D.3.7Routes of administration for this IMPIntravenous use\n\nD.3.8 to D.3.10 IMP Identification Details (Active Substances) D.3.8INN - Proposed INNCYCLOPHOSPHAMIDE D.3.9.1CAS number 50-18-0 D.3.9.4EV Substance CodeSUB06859MIG D.3.10 Strength D.3.10.1Concentration unit mg/kg milligram(s)/kilogram D.3.10.2Concentration typeequal D.3.10.3Concentration number60 D.3.11 The IMP contains an: D.3.11.1Active substance of chemical origin Yes D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No The IMP is a: D.3.11.3Advanced Therapy IMP (ATIMP) No D.3.11.3.1Somatic cell therapy medicinal product No D.3.11.3.2Gene therapy medical product No D.3.11.3.3Tissue Engineered Product No D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No D.3.11.5Radiopharmaceutical medicinal product No D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No D.3.11.7Plasma derived medicinal product No D.3.11.8Extractive medicinal product No D.3.11.9Recombinant medicinal product No D.3.11.10Medicinal product containing genetically modified organisms No D.3.11.11Herbal medicinal product No D.3.11.12Homeopathic medicinal product No D.3.11.13Another type of medicinal product No D.IMP: 3 D.1.2 and D.1.3IMP RoleTest D.2 Status of the IMP to be used in the clinical trial D.2.1IMP to be used in the trial has a marketing authorisation Yes D.2.1.1.1Trade name Fludara (fludarabin phosphate) D.2.1.1.2Name of the Marketing Authorisation holderActavis D.2.1.2Country which granted the Marketing AuthorisationDenmark D.2.5The IMP has been designated in this indication as an orphan drug in the Community No D.2.5.1Orphan drug designation number D.3 Description of the IMP D.3.1Product nameFludara D.3.4Pharmaceutical form Infusion D.3.4.1Specific paediatric formulation No D.3.7Routes of administration for this IMPIntravenous use\n\nD.3.8 to D.3.10 IMP Identification Details (Active Substances) D.3.8INN - Proposed INNFLUDARABINE PHOSPHATE D.3.9.1CAS number 75607-67-9 D.3.9.4EV Substance CodeSUB13897MIG D.3.10 Strength D.3.10.1Concentration unit mg/m2 milligram(s)/square meter D.3.10.2Concentration typeup to D.3.10.3Concentration number25 D.3.11 The IMP contains an: D.3.11.1Active substance of chemical origin Yes D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No The IMP is a: D.3.11.3Advanced Therapy IMP (ATIMP) No D.3.11.3.1Somatic cell therapy medicinal product No D.3.11.3.2Gene therapy medical product No D.3.11.3.3Tissue Engineered Product No D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No D.3.11.5Radiopharmaceutical medicinal product No D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No D.3.11.7Plasma derived medicinal product No D.3.11.8Extractive medicinal product No D.3.11.9Recombinant medicinal product No D.3.11.10Medicinal product containing genetically modified organisms No D.3.11.11Herbal medicinal product No D.3.11.12Homeopathic medicinal product No D.3.11.13Another type of medicinal product No D.IMP: 4 D.1.2 and D.1.3IMP RoleTest D.2 Status of the IMP to be used in the clinical trial D.2.1IMP to be used in the trial has a marketing authorisation Yes D.2.1.1.1Trade name Proleukin (aldesleukin) D.2.1.1.2Name of the Marketing Authorisation holderNovartis D.2.1.2Country which granted the Marketing AuthorisationDenmark D.2.5The IMP has been designated in this indication as an orphan drug in the Community No D.2.5.1Orphan drug designation number D.3 Description of the IMP D.3.1Product nameProleukin D.3.4Pharmaceutical form Infusion D.3.4.1Specific paediatric formulation No D.3.7Routes of administration for this IMPIntravenous use\n\nD.3.8 to D.3.10 IMP Identification Details (Active Substances) D.3.8INN - Proposed INNINTERLEUKIN-2 D.3.9.1CAS number 8000048-25-1 D.3.9.4EV Substance CodeSUB14225MIG D.3.10 Strength D.3.10.1Concentration unit IU international unit(s) D.3.10.2Concentration typeup to D.3.10.3Concentration number675000000 D.3.11 The IMP contains an: D.3.11.1Active substance of chemical origin No D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes The IMP is a: D.3.11.3Advanced Therapy IMP (ATIMP) No D.3.11.3.1Somatic cell therapy medicinal product No D.3.11.3.2Gene therapy medical product No D.3.11.3.3Tissue Engineered Product No D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No D.3.11.5Radiopharmaceutical medicinal product No D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No D.3.11.7Plasma derived medicinal product No D.3.11.8Extractive medicinal product No D.3.11.9Recombinant medicinal product No D.3.11.10Medicinal product containing genetically modified organisms No D.3.11.11Herbal medicinal product No D.3.11.12Homeopathic medicinal product No D.3.11.13Another type of medicinal product No E.1 Medical condition or disease under investigation E.1.1Medical condition(s) being investigated\n\nAdvanced Renal Cell Carcinoma Metastatisk Nyrecancer\n\nE.1.1.1Medical condition in easily understood language\n\nRenal Cell Carcinoma Nyrekræft\n\nE.1.1.2Therapeutic area Diseases [C] - Cancer [C04] MedDRA Classification E.1.2 Medical condition or disease under investigation E.1.3Condition being studied is a rare disease No E.2 Objective of the trial E.2.1Main objective of the trial\n\nTo evaluate toxicity (according to CTCAE version 4.0) and feasibility. At evaluere bivirkninger (ifølge CTCAE version 4.0) og gennemførlighed.\n\nE.2.2Secondary objectives of the trial\n\nTo evaluate treatment related immune responses\n\nTo evaluate clinical response (according to RECIST 1.1 - response rate,\n\nprogressionfree survival and overall survival) At evaluere behandlingsrelateret immunresponser\n\nAt evaluere klinisk respons (ifølge RECIST 1.1 - responsrate,\n\nprogressionsfri overlevelse og samlet overlevelse)\n\nE.2.3Trial contains a sub-study No E.5 End points E.5.1Primary end point(s)\n\nThe primary endpoint is toxicity (according to CTCAE 4.0). Det primære endepunkt er bivirkninger (ifølge CTCAE 4.0).\n\nE.5.1.1Timepoint(s) of evaluation of this end point\n\nThe primary endpoint will be evaluated before treatment, during\n\ntreatment and at follow-up visits untill 6 months after treatment. Det primære endepunkt vil blive evalueret før behandling, under\n\nbehandling og ved opfølgende besøg op til 6 måneder efter behandling.\n\nE.5.2Secondary end point(s)\n\nSecondary endpoints are treatment related immune response and clinical response (according to RECIST 1.1 - response rate, progressionfree\n\nsurvival and overall survival). Sekundære endepunkter er behandlingsrelateret immunrespons og\n\nklinisk respons (ifølge RECIST 1.1 - responsrate, progressionsfri\n\noverlevelse og samlet overlevelse).\n\nE.5.2.1Timepoint(s) of evaluation of this end point\n\nThe secondary endpoints will be evaluated after all patients have\n\nreceived treatment and clinical response is evaluated. Estimated 1 year\n\nafter treatment of last patient. De sekundære endepunkter vil blive evalueret efter at alle patienter har\n\nmodtaget behandling og klinisk respons er vurderet. Estimeret 1 år efter\n\nsidste patients behandling.\n\nE.6 and E.7 Scope of the trial E.6Scope of the trial E.6.1Diagnosis No E.6.2Prophylaxis No E.6.3Therapy Yes E.6.4Safety Yes E.6.5Efficacy Yes E.6.6Pharmacokinetic No E.6.7Pharmacodynamic No E.6.8Bioequivalence No E.6.9Dose response No E.6.10Pharmacogenetic No E.6.11Pharmacogenomic No E.6.12Pharmacoeconomic No E.6.13Others No E.7Trial type and phase E.7.1Human pharmacology (Phase I) No E.7.1.1First administration to humans No E.7.1.2Bioequivalence study No E.7.4Therapeutic use (Phase IV) No E.8 Design of the trial E.8.1Controlled No E.8.1.1Randomised No E.8.1.2Open Yes E.8.1.3Single blind No E.8.1.4Double blind No E.8.1.5Parallel group No E.8.1.6Cross over No E.8.1.7Other No E.8.2 Comparator of controlled trial E.8.2.1Other medicinal product(s) No E.8.2.2Placebo No E.8.2.3Other No E.8.3 The trial involves single site in the Member State concerned Yes E.8.4 The trial involves multiple sites in the Member State concerned No E.8.5The trial involves multiple Member States No E.8.6 Trial involving sites outside the EEA E.8.6.1Trial being conducted both within and outside the EEA No E.8.6.2Trial being conducted completely outside of the EEA No E.8.7Trial has a data monitoring committee No E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial\n\nLVLS Sidste patients sidste besøg\n\nE.8.9 Initial estimate of the duration of the trial E.8.9.1In the Member State concerned years3 E.8.9.1In the Member State concerned months E.8.9.1In the Member State concerned days E.8.9.2In all countries concerned by the trial years3"
    }
}